Ardelyx, Inc. Q3 2025 Earnings Recap

ARDX Q3 2025 October 31, 2025

Get alerts when ARDX reports next quarter

Ardelyx demonstrated strong performance in Q3 2025, driven by robust growth in product revenues, particularly from IBSRELA, which saw a 92% year-over-year increase.

Earnings Per Share Beat

$-0.00 vs $-0.06 est.

+93.3% surprise

Revenue Miss

110329000 vs 119058230 est.

-7.3% surprise

Market Reaction

1-Day -2.31%

5-Day -7.76%

30-Day -4.79%

See ARDX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total product revenue reached $105.5 million, a 15% increase year-over-year.
IBSRELA generated $78.2 million, a record high, with an upward revision of revenue guidance to $270-$275 million for the year.
XPHOZAH contributed $27.4 million in revenue, reflecting a 9% increase from the previous quarter.
Introduction of ARDX-10531, a next-generation NHE3 inhibitor, marks a significant step in expanding the company’s pipeline.
Strong leadership addition with Sue Hohenleitner as CFO, enhancing financial and strategic insights.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ARDX on AllInvestView.